Paper Details

  1. Home
  2. Paper Details

A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.

Author: ChaturvediNagendra K, HatchNathan D, JoshiShantaram S, KlingMatthew, SuttonGarrett L, VoseJulie M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vorinostat, a HDAC inhibitor, and Palbociclib, a CDK4/6 dual-inhibitor, were both effective in suppressing cell growth and inducing apoptosis in mantle cell lymphoma (MCL) cell lines, including therapy-resistant lines. The combination of Vorinostat and Palbociclib was more effective than either drug alone and may represent a novel therapeutic approach for refractory MCL.
Paper Details　
Original Abstract of the Article :
Mantle cell lymphoma (MCL) represents an aggressive B-cell lymphoma with frequent relapse and poor survival. Recently, dysregulated histone-deacetylases (HDACs) and cell cycle CDK-Rb pathway have been shown to be commonly associated with MCL pathogenesis, and are considered promising targets for rel...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10428194.2018.1520986

データ提供：米国国立医学図書館（NLM）

Combating Mantle Cell Lymphoma: A Novel Approach with Vorinostat and Palbociclib

The battle against [mantle cell lymphoma (MCL)] continues, with researchers seeking more effective treatments for this aggressive B-cell lymphoma. This study investigates the efficacy of combining [vorinostat] and [palbociclib], two drugs that target key pathways involved in MCL pathogenesis, in the treatment of MCL. The researchers aimed to assess the single-agent and combination effects of these drugs on MCL cell growth and survival, and to explore the underlying molecular mechanisms.

A Promising Combination: Vorinostat and Palbociclib

The study's results demonstrate that both [vorinostat] and [palbociclib] significantly suppressed cell growth and induced apoptosis in both therapy-resistant and parental MCL cell lines. Importantly, the combination of these drugs synergistically inhibited the activation of key molecules in the CDK4/6-Rb pathway and HDAC activity, resulting in decreased expression of Cyclin-D1 and Bcl-2.

A New Frontier in MCL Treatment

This research offers a promising new approach for the treatment of [mantle cell lymphoma], particularly in refractory cases. The synergistic effects of [vorinostat] and [palbociclib] suggest that this combination therapy could potentially revolutionize the management of MCL. Imagine a vast desert landscape where the most effective resources are strategically combined to create a powerful force. This research represents a similar approach in the fight against MCL, combining the strengths of different agents to achieve a more potent and effective treatment strategy. This study provides a valuable roadmap for future research and clinical trials exploring the potential of this novel combination therapy.

Dr.Camel's Conclusion

This research is a testament to the power of collaboration in scientific exploration, much like the cooperative efforts of desert nomads who pool their resources and expertise to overcome adversity. The synergistic effects of vorinostat and palbociclib in treating mantle cell lymphoma offer a beacon of hope, illuminating a new path toward more effective treatment strategies.

Date :
  1. Date Completed 2020-07-13
  2. Date Revised 2020-07-13
Further Info :

Pubmed ID

30424705

DOI: Digital Object Identifier

10.1080/10428194.2018.1520986

Related Literature

Article Analysis
・Effects of vorinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.